Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:24 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 20,936 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Non-treatment Clear all

Conditions: Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Laboratory Biomarker Analysis, Pembrolizumab; Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Facial Pain
Interventions: TMS, sham TMS coil; Device
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: suramin, carboplatin, paclitaxel, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Inflammatory Bowel Disease
Interventions: Filgotinib, Placebo, Standard of Care; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 21 Years to 65 Years · Male only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more

Conditions: Myelofibrosis
Interventions: Hematopoietic Stem Cell Transplant; Other
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 55 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Single-ventricle
Interventions: Spironolactone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 6 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus, Type 2
Interventions: pioglitazone, rosiglitazone, placebo, Vitamin D, Placebo; Drug · Dietary Supplement
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 1,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 23
States / cities: Long Beach, California • Los Angeles, California • Northridge, California + 19 more

Conditions: Freeman-Sheldon Syndrome, Arthrogryposis Distal Type 2A, Whistling Face Syndrome, Craniocarpotarsal Dysplasia, Craniocarpotarsal Dystrophy, Freeman-Sheldon Syndrome Variant, Sheldon-Hall Syndrome, Arthrogryposis Distal Type 2B, Gordon Syndrome, Arthrogryposis Distal Type 3, Arthrogryposis Distal Type 1, Arthrogryposis, Distal, Type 1A, Arthrogryposis Distal Type 1B, Arthrogryposis, Distal, Craniofacial Abnormalities, Arthrogryposis
Interventions: PTSD Checklist-Civilian (PCL-C), Modified Flanagan Quality of Life Scale, Center for Epidemiologic Studies Depression Scale (CES-D), Functional Enquiry (or Review of Systems) Form, Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire, FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI), Medical Records Review; Other
Lead sponsor: Freeman-Sheldon Research Group, Inc.; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Buckhannon, West Virginia

Conditions: Brain Tumor, Glioblastoma, Anaplastic Glioma
Interventions: everolimus, sorafenib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Small Cell Lung Cancer
Interventions: LGX818; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Parkinson's Disease
Interventions: TNM Device; Device
Lead sponsor: Scion NeuroStim; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hot Flashes, Night Sweats
Interventions: Estradiol; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 235 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Advanced Solid Tumors
Interventions: Elimusertib (BAY1895344), Pembrolizumab (Keytruda®); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more

Conditions: Parenting, Adolescent - Emotional Problem, Mental Disorder in Adolescence
Interventions: Parenting Wisely Residential Treatment (PWRT), TAU; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 11 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Oral Leukoplakia
Interventions: Lozenge Intake; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Low Back Pain
Interventions: Restrained Sitting Treatment; Other
Lead sponsor: Liberty Mutual Research Institute for Safety; Industry
Eligibility: 30 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Hopkinton, Massachusetts

Conditions: Intracerebral Aneursym
Interventions: MicroVention Hydrogel coil, Non-hydrogel coils; Device
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 90 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 11
States / cities: Carmichael, California • Los Angeles, California • Gainesville, Florida + 8 more

Conditions: Leukemia, Lymphoma
Interventions: aldesleukin, allogeneic natural killer cells, rituximab, cyclophosphamide, fludarabine phosphate; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Endometrial Neoplasms, Ovarian Cancer, Solid Tumor, Head and Neck Cancer
Interventions: COM701 in combination with BMS-986207 and nivolumab.; Drug
Lead sponsor: Compugen Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 9
States / cities: Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more

Conditions: Knee Osteoarthritis
Interventions: Duloxetine, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices; Drug · Combination Product · Procedure + 2 more
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 1,937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 24
States / cities: Sacramento, California • San Diego, California • Aurora, Colorado + 19 more

Conditions: Determine Effectiveness of Theraskin in the Treatment of DFU and VLU
Interventions: Human Allograft (Theraskin); Other
Lead sponsor: Solsys Medical LLC; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Diabetes, Diabetic Foot, Diabetic Foot Ulcer
Interventions: DV-SSP Imaging; Diagnostic Test
Lead sponsor: SpectralMD; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Encino, California • Los Angeles, California • Lake Success, New York + 8 more

Conditions: Venous Thromboembolism
Interventions: Enoxaparin; Drug
Lead sponsor: Hamilton Health Sciences Corporation; Other
Eligibility: Up to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Small Cell Lung Cancer
Interventions: Docetaxel, Oxaliplatin, Bevacizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Transcranial Magnetic Stimulation (TMS) for Trigeminal Neuralgia

Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Fibrosis and the Fontan

Thiazolidinedione Intervention With Vitamin D Evaluation

Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome

Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease

Comparison of Hormonal Therapy: Mediating Hot Flashes Tapering Regimens for Mediating Hot Flashes

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

Optimizing Residential Treatment Gains for Adolescents

A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia

Limiting Trunk Flexion as a Self-treatment for Low Back Pain

HydroCoil Cerebral Aneurysm Treatment Trial

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

Clinical Trial to Examine Effectiveness of a Human Allograft for Treatment of DFU and VLU

Wound Assessment Using Spectral Imaging US

Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)